Zerion
Manufacturing · Denmark · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Fruebjergvej 3, Copenhagen, Capital Regi...Website
www.zerion.euRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Zerion
Zerion Pharma is a pharmaceutical development company focused on transforming drug formulation through its innovative Dispersome® technology, which enhances the solubility of poorly soluble drugs. The company aims to improve bioavailability and therapeutic outcomes for patients by utilizing natural, safe excipients in its formulations. Zerion Pharma collaborates with prominent pharmaceutical partners to advance drug solubility and enhance patient well-being. Their proprietary technology is supported by over a decade of research and validated through peer-reviewed studies.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zerion your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Zerion is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Zerion recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Zerion
Zerion, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Zerion launches new products
Check if Zerion has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Zerion had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Zerion has new funding data
Recommended Actions
Reach out to Masked Content who joined Zerion as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Zerion is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Zerion is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zerion.
Zerion Tech Stack
A closer look at the technologies used by Zerion
Zerion News & Media
Zerion Pharma’s Dispersome® technology published in two peer-reviewed papers through partnerships with pharmaceutical companies
June 8, 2023 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces the publication of joint experimental work on its Dispersome[®] technology in the International Journal of Pharmaceutics and Pharmaceutical Research, two peer-reviewed papers. The work behind the publications originated from two partnership projects, one with Bayer AG and one with Novartis Pharma AG. The former can be accessed here (https://doi.org/10.1016/j.ijpharm.2023.122693) and showcases the interplay between dZerion Pharma and Insud Pharma announce collaboration to develop Dispersome® formulations of marketed drug products
- The two companies have started collaborating on the first two drug products and expect to expand their portfolio. AUGUST 29, 2022 (COPENHAGEN, Denmark). The Danish pharmaceutical company Zerion Pharma A/S (ZERION) and the Spanish pharmaceutical group Insud Pharma, SL today are announcing their collaboration to develop and commercialize drug products applying ZERION’s solubility enhancing Dispersome® technology. ZERION will develop Dispersome® formulations of marketed drug products while INSUDZerion Pharma and Hovione extend partnership to cover use of the Dispersome® technology platform in nutraceuticals
AUGUST 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (ZERION) and Hovione today announced an extension of their collaboration on ZERION’s Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor bioavailability and consequently limits the physiological effect of the supplement. To overcome these limitations, the two companies will collaborate and apply the solubility enhancing Dispersome® technology forArla Food Ingredients and Zerion Pharma complete long-term supply agreement for beta-lactoglobulin (Lacprodan® BLG-100)
February 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) announces today that it has executed a long-term agreement with Arla Food Ingredients covering the supply of its Lacprodan® BLG-100 for use as a pharmaceutical excipient in connection with ZERION’s patented Dispersome® technology. Arla Foods Ingredients is a global leader in value added whey ingredients. Among others, serving the markets within clinical and early life nutrition. The two companies announced their intention to e
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Zerion
Sign Up For FreeTo access detailed company insights
Zerion Pharma is a pharmaceutical development company focused on transforming drug formulation through its innovative Dispersome® technology, which enhances the solubility of poorly soluble drugs. The company aims to improve bioavailability and therapeutic outcomes for patients by utilizing natural, safe excipients in its formulations. Zerion Pharm... Read More
